Skip to main content
    S

    Spyre Therapeutics Inc. (SYRE)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $99.37
    -4.63 (-4.45%)

    Market Cap: $9.88B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Spyre Therapeutics Inc. (SYRE) Financials: Revenue, Profit and Cash Flow

    Updated Nov 3, 2026. Financial statements from company filings, amounts in US dollars.

    Spyre Therapeutics reported revenue of $0 for the fiscal year ended Dec 31, 2025. That year, net income was -$155.20M, operating cash flow was -$169.25M and free cash flow was -$169.25M. The quarter ended Sep 30, 2026 had revenue of $0 and net income of -$96.12M.

    Revenue and Margins

    The company reported no revenue in the fiscal year ended Dec 2025, with an operating loss of $209.56M.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$0N/AN/AN/AN/A
    Dec 2024$0-100.0%N/AN/AN/A
    Dec 2023$886.00K-62.0%100.0%-27348.0%-38238.1%
    Dec 2022$2.33M-87.6%100.0%-3640.2%-3598.8%
    Dec 2021$18.74MN/A100.0%-350.3%-351.1%
    Dec 2020$0N/AN/AN/AN/A
    Dec 2019$0-100.0%N/AN/AN/A
    Dec 2018$3.89M-25.3%100.0%-1169.3%-1140.6%
    Dec 2017$5.21M+12.5%100.0%-531.7%-523.3%
    Dec 2016$4.63MN/A100.0%-473.3%-468.8%
    Annual, fiscal years ended Dec 2016 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss narrowed from the year before. In the quarter ended Sep 2026, the net loss widened from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Revenue$0$0$886.00K$2.33M$18.74M$0$0$3.89M$5.21M$4.63M
    Gross profit$0$0$886.00K$2.33M$18.74M$0$0$3.89M$5.21M$4.63M
    Research and development$171.65M$162.79M$219.69M$58.58M$57.07M$59.64M$64.60M$36.72M$22.82M$18.14M
    Operating income-$209.56M-$208.57M-$242.30M-$84.78M-$65.65M-$81.48M-$80.33M-$45.46M-$27.68M-$21.91M
    Net income-$155.20M-$208.02M-$338.79M-$83.81M-$65.80M-$80.89M-$78.25M-$44.35M-$27.24M-$21.70M
    EBITDA-$188.19MN/AN/A-$83.14M-$63.22M-$80.42MN/AN/A-$27.39M-$21.71M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$0$0$0$90.49M$0$0$0$0$0$0$0$1.04M
    Gross profit$0$0$0$45.25M$0$0$0N/A$0$0$0$78.00K
    Operating income-$105.72M-$41.64M-$45.64M-$57.17M-$56.89M-$41.94M-$53.57M-$61.25M-$55.39M-$44.15M-$47.77M-$45.91M
    Net income-$96.12M-$36.20M-$69.00M-$62.53M-$11.18M-$36.72M-$44.77M-$56.30M-$69.03M-$38.84M-$43.86M-$63.18M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents of $85.72M were 11.0% of total assets of $777.78M, against total liabilities of $62.55M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Total assets$777.78M$608.48M$341.86M$71.14M$109.93M$161.62M$83.18M$77.74M$56.08M$67.06M
    Current assets$777.78M$608.47M$341.53M$62.26M$98.89M$149.79M$74.50M$76.67M$54.99M$66.42M
    Cash and equivalents$85.72M$89.42M$188.89M$34.86M$15.14M$90.09M$19.25M$22.46M$12.82M$47.75M
    Total liabilities$62.55M$90.68M$73.29M$20.84M$25.98M$21.79M$23.10M$10.31M$5.74M$4.10M
    Short-term debtN/AN/AN/A$625.00K$436.00K$319.00K$379.00KN/AN/AN/A
    Shareholder equity$715.24M$517.80M$184.02M$50.30M$83.94M$139.83M$60.08M$67.43M$50.34M$62.97M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$1.10B$1.17B$763.95M$777.78M$504.60M$538.83M$569.78M$608.48M$421.09M$436.07M$487.60M$341.86M
    Total liabilities$48.19M$71.86M$93.14M$62.55M$49.50M$83.06M$87.17M$90.68M$93.70M$61.68M$81.93M$157.84M
    Cash and equivalents$82.73M$162.01M$97.19M$85.72M$64.90M$81.66M$48.49M$89.42M$71.58M$45.14M$227.55M$188.89M
    Shareholder equity$1.05B$1.10B$670.81M$715.24M$455.10M$455.77M$482.61M$517.80M$327.39M$374.38M$152.27M$184.02M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Operating cash flow-$169.25M-$157.41M-$99.91M-$80.14M-$53.72M-$75.78M-$65.69M-$32.19M-$24.61M-$18.84M
    Capital expenditures$0$0$0$38.00K$573.00K$4.28M$1.49M$422.00K$619.00K$212.00K
    Free cash flow-$169.25M-$157.41M-$99.91M-$80.18M-$54.29M-$80.06M-$67.18M-$32.62M-$25.23M-$19.05M
    Investing cash flow-$143.47M-$353.29M-$108.39M$57.01M-$22.62M-$7.60M-$1.74M-$15.23M-$22.53M-$12.08M
    Financing cash flow$309.02M$410.91M$361.08M$42.68M$1.39M$154.51M$65.72M$57.07M$12.21M$49.37M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow-$77.50M-$69.88M-$57.37M-$44.58M-$37.12M-$46.56M-$40.99M-$37.20M-$29.42M-$62.25M-$28.54M-$31.04M
    Free cash flowN/AN/A-$57.37M-$44.58M-$37.12M-$46.56M-$40.99M-$37.20M-$29.42M-$62.25M-$28.54M-$31.04M
    Last 12 quarters

    Frequently Asked Questions About SYRE

    What is Spyre Therapeutics' annual revenue?

    Spyre Therapeutics reported revenue of $0 for the fiscal year ended Dec 31, 2025.

    Is Spyre Therapeutics profitable?

    No. Spyre Therapeutics reported net income of -$155.20M for the fiscal year ended Dec 31, 2025.

    How much free cash flow does SYRE generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$169.25M minus capital expenditures of $0 produced free cash flow of -$169.25M.

    How much debt does Spyre Therapeutics have?

    The balance sheet dated Dec 31, 2025 reported cash and equivalents of $85.72M.